Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights:

Global Nanoparticle Drug Delivery Market Opportunity > USD 300 Billion by 2028
Nanoparticle Drug Deliver Price and Dosage Insight By Therapeutic: Cancer, Anemia, Autoimmune Diseases, Neurological Disorders

Global Nanoparticle Drug Market Regional Analysis: US, Europe, China, Japan, India, Taiwan, South Korea, Canada

Nanoparticle Therapeutics Approved Drugs Sales Insight: 15 Drugs
Nanoparticle Therapeutics Approved Drugs Sales Forecast 2028: 15 Drugs
Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company and Indication: > 400 Drugs
Nanoparticle Drug Delivery - Market Trend and Patent Distribution Analysis

During the last few decades, there has been enormous development in the field of delivery systems to provide therapeutic agents or natural based active compounds to the target location for the management of several diseases. Several drug delivery approaches have been successfully employed in recent times, however there are still certain challenges that need to be addresses and an advanced technology need to be developed for successful delivery of drugs to its target sites. In order to overcome these challenges, the nanoparticle based drug delivery systems are currently been studied that will facilitate the advanced system of drug delivery.

Nanoparticle drug delivery is the emerging branch which utilizes nanotechnology in the prevention and treatment of various diseases using the nanoscale materials, such as biocompatible nanoparticles and nanorobots for delivery of drug to target location. Several biopolymeric nanoparticles can be utilized for drug delivery systems such as chitosan, xanthum gum, cellulose, liposome, dendrimers, and others. Liposome drug delivery approach is one of the most promising approaches and held the maximum share in the global nanoparticle drug delivery market.

Companies in the liposome drug delivery market are increasing their focus on drug delivery nanosystems involving major antiviral classes and their transport across specific barriers at cellular and intracellular levels. Thus, liposomes hold promising potentials in ongoing research studies being carried out by healthcare companies for the treatment of coronavirus. Further, several pharmaceutical companies have also entered into collaboration or partnerships to drive this segment in forecast period. For instance, Encapsula NanoSciences has extensive collaboration with academic research laboratories and is currently working with synthetic chemists and cancer biologists at a major university in the development of new anti-tumor compounds that require a liposome delivery system to be dosed in vivo. Moreover, Lipella Pharmaceuticals Inc. has been funded by the National Institutes of Health Small Business Innovation and Research (SBIR) to develop intravesical liposome nanoparticles to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS).

Apart from oral drugs, researchers have also expanded the idea of nanotechnology towards vaccine development. So far, two nanoparticle formulated, mRNA based COVID-19 vaccines have been developed, clinically tested and marketed during the ongoing pandemic. These vaccines are BNT162b2 by Pfizer/BioNTech and mRNA-1273 by Moderna. Apart from this, two vaccines are present under development such as NVX-CoV2373 vaccine (Novavax).

Further to mitigate the high cost associated with nanoparticle drugs, the research is also directed towards the development of cost-effective nanoparticle based generic drugs. The generic nanoparticle drug has also seen substantial rise in production as they are less expensive than branded and do not require extensive research and testing. Several pharmaceutical companies including Mylan, Teva, Actavis, Lupin Laboratories, Sun Pharma, and others have launched their generic versions in the market, which have shown high acceptance.

As per our report findings, the global nanoparticle drug delivery market is expected to surpass US$ 300 Billion by 2028. The market has high potential for growth which is attributed to the increasing number of patients suffering from chronic diseases, increasing research and development spending by pharmaceutical giants in the region with a robust clinical pipeline of nanoparticle drug delivery systems. In addition, the rising disposable population leading to increasing awareness towards health and lifestyle is also likely to propel the market growth. Further, the availability of wide range of generic drugs which increasing the accessibility among general population also propels the growth of market during the forecast period.

The report Nanoparticle drug delivery market provides comprehensive analysis on the commercially available nanomedicines along with their price, dosage, generic availability, and sales analysis. Moreover, in-depth analysis on the ongoing clinical trials in the report is also included in the report. Further, key players and their strategies are thoroughly analyzed to provide competitive outlook to the industry.

Nanoparticles – New Era of Drug Delivery Methodology

1.1 Targeted Drug Delivery by Nanoparticles

1.2 Enhancing the Therapeutics Efficacy

Need for Nanoparticle Drug Delivery

2.1 Limitations of Traditional Drug Delivery Techniques

2.2 Rising Demand for Better Targeted Drug Delivery Techniques in the Oncology Segment

2.3 Better Therapeutic Outcome than Conventional Drug Delivery Methods

Importance of Nanoparticle Drug Delivery in Cancer Therapy

3.1 Wide Application of Nanoparticles in Cancer Therapy

3.2 Mechanisms of Nanoparticle Internalization in Cancer Cells for Imaging and Therapy

3.3 Role of Nanoparticles in Better Diagnosis of Cancer

Nanoparticle Drug Delivery Techniques

4.1 Nanocrystals

4.2 Liposomes

4.3 Dendrimers

4.4 Micelle Based Drug Delivery

4.5 Polymeric Nanoparticles

4.6 Metal Based Nanoparticles (Gold, iron oxide)

4.7 Fullerenes and Carbon Nanotube

4.8 Quantum Dots Delivery

Global Nanoparticle Drug Market Overview

5.1 Current Market Scenario

5.2 Future Market Opportunity

Global Nanoparticle Drug Market Regional Analysis

6.1 US

6.2 Europe

6.3 China

6.4 Japan

6.5 India

6.6 Taiwan

6.7 South Korea

6.8 Canada

Global Nanoparticle Drug Market by Indication

7.1 Oncology

7.2 Autoimmune Diseases

7.3 Iron Deficiency Anemia

7.4 Neurological Disorders

Cancer Nanoparticle Therapeutics - Price and Dosage Insight

8.1 Liposomal Doxorubicin

8.2 Paclitaxel Protein-Bound

8.3 Megace ES (Enhanced Stability)

8.4 Vyxeos (Cytarabine and Daunorubicin)

8.5 Marqibo

8.6 Oncaspar (Pegaspargase)

8.7 Onivyde

8.8 Cynviloq

8.9 Hensify

8.10 Paclical

8.11 Mepact

8.12 Lipusu

8.13 Eligard

Anemia Nanoparticle Therapeutics - Price and Dosage Insight

9.1 Ferumoxytol (Feraheme)

9.2 Injectafer (Ferric Carboxymaltose)

9.3 Venofer

9.4 Ferrlecit

9.5 Infed

9.6 Mircera

Autoimmune Diseases Nanoparticle Therapeutics - Price and Dosage Insight

10.1 Copaxone (Glatiramer)

10.2 Cimzia

10.3 Plegridy (Peginterferon beta-1a)

10.4 Krystexxa (Pegloticase)

10.5 Zilretta (Triamcinolone Acetonide)

Neurological Disorders Nanoparticle Therapeutics - Price and Dosage Insight

11.1 Onpattro (Patisiran)

11.2 Visudyne (Verteporfin)

Price and Dosage Analysis of Commercially Available Other Nanoparticle Therapeutics

12.1 Amphotericin B Liposomal

12.2 Rapamune

12.3 Emend (Aprepitant Nanocrystal)

12.4 Triglide – Nanocrystal Version of Tricor

12.5 Neulasta

12.6 Ritalin (Methylphenidate)

12.7 Renagel (Sevelamer)

12.8 Abelcet

12.9 Somavert (Pegvisomant)

12.10 Rebinyn/Refixia

12.11 Invega (Paliperidone)

Global Nanoparticle Therapeutics Approved Drus – Sales Analysis and Forecast Till 2028

13.1 Ambisome

13.2 Abraxane

13.3 Vyxeos

13.4 Onpattro

13.5 Neulasta

13.6 Somavert

13.7 Zilretta

13.8 Copaxone

13.9 Mircera

13.10 Injectafer

13.11 Venofer

13.12 Onivyde

13.13 Cimzia

13.14 Plegridy

13.15 Krystexxa

Global Nanoparticle Drug Clinical Trial Insights

14.1 By Status

14.2 By Phase

14.3 By Region

Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company and Indication

15.1 Research

15.2 Preclinical

15.3 Clinical

15.4 Phase-I

15.5 Phase-I/II

15.6 Phase-II

15.7 Phase-II/III

15.8 Phase-III

15.9 Registered

Marketed Nanoparticles Drug Clinical Insight

Nanoparticle Drug Delivery Market Dynamics

17.1 Driving Factors of Nanoparticle Drug Delivery Market

17.2 Challenging Aspects of Nanoparticle Drug Delivery Segment

Competitive Landscape

18.1 AbbVie

18.2 Amgen

18.3 Alnylam Pharmaceuticals

18.4 Arrowhead Pharmaceuticals

18.5 BioGen

18.6 Bristol Myers Squibb

18.7 Clene Nanomedicine

18.8 Horizon Therapeutics

18.9 Merck

18.10 Nanobiotix

18.11 Nanospectra Biosciences

18.12 Novartis

18.13 Pfizer

18.14 Tandem Nano

Figure 1-1: Evolution of Nanoparticle Drug Delivery

Figure 1-2: Different Drug Delivery Routes

Figure 1-3: Organic Nanoparticles Used in Drug Delivery

Figure 2-1: Limitations of Traditional Drug Delivery Therapy

Figure 2-2: Superior Characteristic of Nanoparticle Drug Delivery

Figure 3-1: Inorganic Nanoparticles Used in Drug Delivery

Figure 3-2: Application of Nanoparticles in Diagnosis

Figure 4-1: Nanoparticles Market Segmentation by Types

Figure 4-2: Liposome Drug Delivery in Action

Figure 4-3: Dendrimer Nanoparticle in Drug Delivery

Figure 4-4: Gold Nanoparticles in Drug Delivery

Figure 4-5: Fullerenes Being Used as Vectors (Carrying Agents)

Figure 4-6: Quantum Dots in Cancer Therapy

Figure 5-1: Global – Nnaoparticle Drug Market Size (US$ Billion), 2020 and 2021

Figure 5-2: Global – Nnaoparticle Drug Market Size by Region (US$ Billion), 2021

Figure 5-3: Global – Nnaoparticle Drug Market Size by Region (%), 2021

Figure 5-4: Global – Nanoparticle Drug Market Size (US$ Million), 2022 - 2028

Figure 6-1: US vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-2: US vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-3: US – Nanoparticle Drug Market Size (US$ Billion), 2022 - 2028

Figure 6-4: Europe vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-5: Europe vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-6: Europe – Nanoparticle Drug Market Size (US$ Billion), 2022 - 2028

Figure 6-7: China vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-8: China vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-9: China – Nanoparticle Drug Market Size (US$ Billion), 2022 - 2028

Figure 6-10: Japan vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-11: Japan vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-12: Japan – Nanoparticle Drug Market Size (US$ Billion), 2022 - 2028

Figure 6-13: India vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-14: India vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-15: India – Nanoparticle Drug Market Size (US$ Billion), 2022 - 2028

Figure 6-16: Taiwan – Nanoparticle Drug Market Size (US$ Billion), 2021 - 2028

Figure 6-17: South Korea vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-18: South Korea vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-19: South Korea – Nanoparticle Drug Market Size (US$ Billion), 2022 - 2028

Figure 6-20: Canada vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-21: Canada vs. ROW – Nanoparticle Drug Market Size (US$ Billion), 2021

Figure 6-22: Canada – Nanoparticle Drug Market Size (US$ Billion), 2022 - 2028

Figure 7-1: Global – Cancer Incidences and Deaths (Million), 2020

Figure 7-2: Global – Cancer Nanoparticle Drug Market Size (US$ Billion), 2021 - 2028

Figure 7-3: Global – Autoimmune Disease Nanoparticle Drug Market Size (US$ Billion), 2021 - 2028

Figure 7-4: Global – Iron Deficiency Anemia Nanoparticle Drug Market Size (US$ Billion), 2021 - 2028

Figure 7-5: Global – Neurological Disease Nanoparticle Drug Market Size (US$ Billion), 2021 - 2028

Figure 8-1: Doxorubicin Liposomal - Approval Year by Region

Figure 8-2: US - Doxil FDA Approval and First Generic Approval Year

Figure 8-3: Doxil - Cost of 10ml and Per Unit Cost of 2mg/ml Intravenous Dispersion (US$), February’2022

Figure 8-4: Doxil - Cost of 25ml and Per Unit Cost of 2mg/ml Intravenous Dispersion (US$), February’2022

Figure 8-5: Liposomal Doxorubicin - Cost of 10ml and Per Unit Cost of 2mg/ml Intravenous Dispersion (US$), February’2022

Figure 8-6: Liposomal Doxorubicin - Cost of 25ml and Per Unit Cost of 2mg/ml Intravenous Dispersion (US$), February’2022

Figure 8-7: Doxil- Dosage analysis for Ovarian Cancer (mg/m2)

Figure 8-8: Doxil - Dosage Analysis for Kaposi's sarcoma

Figure 8-9: Liposomal Doxorubicin - Dosage Analysis in Multiple Myeloma

Figure 8-10: US - Abraxane FDA Approval and Patent Expiration Year

Figure 8-11: Europe - Abraxane EMA Approval and Patent Expiration Year

Figure 8-12: US - Abraxane FDA Approval by Indication

Figure 8-13: UK – Cost of Supply of Abraxane 100mg Powder for Injection (GBP/US$), February’2022

Figure 8-14: Abraxane – Cost of Supply of 100mg Powder for Injection by Region (US$), February’2022

Figure 8-15: Abraxane - Recommended Dose (mg/m2) by Cancer Types

Figure 8-16: Dosage Analysis - Megace v/s Megace ES (mg/day)

Figure 8-17: US – Megace ES Approval and First Generic Approval Year

Figure 8-18: US – Megace ES Patent Approval and Expiration Year

Figure 8-19: Megace ES - Cost of 150ml and Per Unit Cost of 625mg/5ml Oral Suspension (US$), February’2022

Figure 8-20: Vyxeos – FDA Approval Year by Indication

Figure 8-21: Vyxeos - Approval Year by Region

Figure 8-22: Vyexos – Patent Expiration by Region

Figure 8-23: Vyxeos - Cost of 2 Powders and Per Unit Cost of 100mg-44mg Intravenous Powder (US$), February’2022

Figure 8-24: Vyxeos - Cost of 5 Powders and Per Unit Cost of 100mg-44mg Intravenous Powder (US$), February’2022

Figure 8-25: UK – Cost of Supply of Vyxeos 100mg Powder for Injection (GBP/US$), February’2022

Figure 8-26: Vyxeos - Recommended Dose of Induction and Consolidation Cycle (mg/m2)

Figure 8-27: Marqibo - Cost of Single Cycle, Monthly and Annual Treatment Cost (US$), February’2022

Figure 8-28: Oncaspar - Approval Year by Region

Figure 8-29: US - Cost of 5ml and Per Unit Cost of Oncaspar Injectable Solution (US$), February’2022

Figure 8-30: Oncaspar - Recommended Dose by Age (Units/m2)

Figure 8-31: US - Onivyde FDA Approval and Patent Expiration Year

Figure 8-32: Europe - Onivyde EMA Approval and Patent Expiration Year

Figure 8-33: US - Cost of 10ml and Per Unit Cost of Onivyde 4.3mg/ml Intravenous Dispersion (US$), February’2022

Figure 8-34: UK - Cost of 10ml and Per Unit Cost of Onivyde 4.3mg/ml Intravenous Dispersion (GBP/US$), February’2022

Figure 8-35: Onivyde - Cost of Single Cycle, Monthly and Annual Treatment Cost (US$), February’2022

Figure 8-36: India - Genexol PM Cost of 100mg Injection (INR/US$), February’2022

Figure 8-37: Paclical/Apealea - Approval Year by Region

Figure 8-38: Apealea/Paclical - Recommended Standard Dose and Dose Reductions (mg/m2)

Figure 8-39: UK – Cost of 4mg Mepact Powde (GBP/US$), February’2022

Figure 8-40: Mepact - Cost of Single Cycle and Treatment Cost (GBP/US$), February’2022

Figure 8-41: Eligard – Price for Supply of Subcutaneous Powder by Strength (US$), February’2022

Figure 9-1: US – Feraheme Approval and First Generic Approval Year

Figure 9-2: US - Ferraheme Patent Approval and Expiration Year

Figure 9-3: Feraheme - Cost of 17ml and Per Unit Cost of 30mg/ml Intravenous Solution (US$), February’2022

Figure 9-4: Feraheme - Cost of 170ml and Per Unit Cost of 30mg/ml Intravenous Solution (US$), February’2022

Figure 9-5: Ferumoxytol - Cost of 17ml and Per Unit Cost of 30mg/ml Intravenous Solution (US$), February’2022

Figure 9-6: US – Injectafer Patent Approval and Expiration Year

Figure 9-7: US - Cost of 15ml and Per Unit Cost of Injectafer 50mg/ml Intravenous Solution (US$), February’2022

Figure 9-8: US - Cost of 25ml and Per Unit Cost of Venofer 20mg/ml Intravenous Solution (US$), February’2022

Figure 9-9: US - Cost of 50ml and Per Unit Cost of Venofer 20mg/ml Intravenous Solution (US$), February’2022

Figure 9-10: US - Cost of 125ml and Per Unit Cost of Venofer 20mg/ml Intravenous Solution (US$), February’2022

Figure 9-11: UK - Cost of 5 Vials and Per Unit Cost of Venofer 100mg/5ml Solution (GBP/US$), February’2022

Figure 9-12: Venofer – Recommended Initial Dose by Indication (mg)

Figure 9-13: Ferrlecit - Cost of 50ml and Per Unit Cost of 12.5mg/ml Intravenous Solution (US$), February’2022

Figure 9-14: Sodium Ferric Gluconate - Cost of 50ml and Per Unit Cost of 12.5mg/ml Intravenous Solution (US$), February’2022

Figure 9-15: Ferrlecit – Minimum and Maximum Recommended Dose for Adult Patients (mg)

Figure 9-16: Infed - Cost of 20ml and Per Unit Cost of 50mg/ml Intravenous Solution (US$), February’2022

Figure 9-17: US – Mircera FDA Approval Year by Indication

Figure 9-18: US- Cost of 0.3ml and Per Unit Cost of Mircera 30mcg Intravenous Solution (US$), February’2022

Figure 9-19: US- Cost of 0.3ml and Per Unit Cost of Mircera 50mcg Intravenous Solution (US$), February’2022

Figure 9-20: US- Cost of 0.3ml and Per Unit Cost of Mircera 75mcg Intravenous Solution (US$), February’2022

Figure 9-21: US- Cost of 0.3ml and Per Unit Cost of Mircera 100mcg Intravenous Solution (US$), February’2022

Figure 9-22: US- Cost of 0.3ml and Per Unit Cost of Mircera 150mcg Intravenous Solution (US$), February’2022

Figure 9-23: US- Cost of 0.3ml and Per Unit Cost of Mircera 200mcg Intravenous Solution (US$), February’2022

Figure 9-24: UK - Cost of Supply of 30 Somavert Subcutaneous Powders by Strength (GBP/US$), February’2022

Figure 10-1: Copaxone – FDA Orphan Designation Year by Indication

Figure 10-2: Copaxone – FDA Approval and 1st Generic Approval Year

Figure 10-3: Copaxone – Price for 30ml Supply and Price Per ml of 20mg/ml Subcutaneous Solution (US$), February’2022

Figure 10-4: Copaxone – Price for 12ml Supply and Price Per ml of 40mg/ml Subcutaneous Solution (US$), February’2022

Figure 10-5: Cimzia – FDA Approval Year by Indication

Figure 10-6: Cimzia - Approval Year by Region

Figure 10-7: US - Cimzia FDA Approval Year and Patent Expiration

Figure 10-8: UK - Cost of 2 Cartridges and Per Unit Cost of Cimzia 200mg/ml Solution (GBP/US$), February’2022

Figure 10-9: Plegridy – FDA Approval Year by Administration

Figure 10-10: US - Plegridy FDA Approval and Patent Expiration Year

Figure 10-11: Europe - Plegridy EMA Approval and Patent Expiration Year

Figure 10-12: UK - Cost of 2 Injections and Per Unit Cost of Plegridy 125mg Injection (GBP/US$), February’2022

Figure 10-13: Plegridy – Recommended Subcutaneous Dose for Multiple Sclerosis (mg)

Figure 10-14: US - Krystexxa FDA Approval and Patent Expiration Year

Figure 10-15: Krystexxa - Cost of Single Cycle, Monthly and Annual Treatment Cost (US$), February’2022

Figure 10-16: US – Zilretta Patent Issue and Expiration Year

Figure 11-1: Onpattro - Approval Year by Region

Figure 11-2: US – Onpattro Patent Approval and Expiration Year

Figure 11-3: US - Cost of 5ml and Per Unit Cost of Onpattro Intravenous Solution (US$), February’2022

Figure 11-4: UK - Cost of 5ml and Per Unit Cost of Onpattro Itravenous Solution (GBP/US$), February’2022

Figure 11-5: UK – Cost of Supply of Visudyne 15mg Powder for Injection (GBP/US$), February’2022

Figure 11-6: Visudyne – Cost of Supply of 15mg Powder for Injection by Region (US$), February’2022

Figure 12-1: Amphotericin B – Availability by Concentration (mg/vial)

Figure 12-2: Conventional Amphotericin B- Dosage Analysis for Adult Fungal Infections (mg/kg)

Figure 12-3: Amphotericin B - Dosage Analysis in Pediatric Fungal Infection (mg/kg)

Figure 12-4: Liposomal Amphotericin B- Dosage Analysis by Indication (mg/kg)

Figure 12-5: US - Rapamune FDA Approval and First Generic Approval Year

Figure 12-6: Rapamune - Cost of 60ml and Per Unit Cost of 1mg/ml Oral Solution (US$), February’2022

Figure 12-7: Rapamune - Cost of 100 Tablets and Per Unit Cost of 0.5mg Oral Tablet (US$), February’2022

Figure 12-8: Rapamune - Cost of 100 Tablets and Per Unit Cost of 1mg Oral Tablet (US$), February’2022

Figure 12-9: Rapamune - Cost of 100 Tablets and Per Unit Cost of 2mg Oral Tablet (US$), February’2022

Figure 12-10: Sirolimus - Cost of 60ml and Per Unit Cost of 1mg/ml Oral Solution (US$), February’2022

Figure 12-11: Sirolimus - Cost of 100 Tablets and Per Unit Cost of 0.5mg Oral Tablet (US$), February’2022

Figure 12-12: Sirolimus - Cost of 100 Tablets and Per Unit Cost of 1mg Oral Tablet (US$), February’2022

Figure 12-13: Sirolimus - Cost of 100 Tablets and Per Unit Cost of 2mg Oral Tablet (US$), February’2022

Figure 12-14: Rapamune - Dosage for Low Immune Risk Patients (mg)

Figure 12-15: Rapamune - Dosage for High Immunologic Risk (mg)

Figure 12-16: Emend - Approval Year by Region

Figure 12-17: US - Emend Approval and First Generic Approval Year

Figure 12-18: Emend - Cost of 2 Capsules and Per Unit Cost of 80mg Oral Capsule (US$), February’2022

Figure 12-19: Emend - Cost of 3 Kits and Per Unit Cost of 125mg-80mg Kit (US$), February’2022

Figure 12-20: UK - Cost of 2 Capsules and Per Unit Cost of Emend 80mg Oral Capsule (GBP/US$), February’2022

Figure 12-21: UK - Cost of 5 Capsules and Per Unit Cost of Emend 125mg Oral Capsule (GBP/US$), February’2022

Figure 12-22: Emend - Recommended Dosing for the Prevention of Nausea and Vomiting in Adult Patients (mg/day)

Figure 12-23: Emend - Recommended Dosing for the Prevention of Nausea and Vomiting in Pediatric Patients (mg/kg)

Figure 12-24: Emend – Maximum Recommended Dosing for the Prevention of Nausea and Vomiting in Pediatric Patients (mg/kg)

Figure 12-25: Triglide - Cost of 30 Tablets and Per Unit Cost of 50mg Oral Tablet (US$), February’2022

Figure 12-26: Triglide - Cost of 30 Tablets and Per Unit Cost of 160mg Oral Tablet (US$), February’2022

Figure 12-27: Triglide - Cost of 15 Tablets and Per Unit Cost of 160mg Oral Tablet (US$), February’2022

Figure 12-28: US - Cost of 0.6ml and Per Unit Cost of Neulasta Subcutaneous Solution (US$), February’2022

Figure 12-29: UK – Cost of 6mg/0.6ml Neulasta Subcutaneous Solution (GBP/US$), February’2022

Figure 12-30: Neulasta – Recommended Dosage by Weight (mg)

Figure 12-31: US - Ritalin FDA Approval and First Generic Approval Year

Figure 12-32: Ritalin - Cost of 100 Tablets and Per Unit Cost of 5mg Oral Tablet (US$), February’2022

Figure 12-33: Ritalin - Cost of 100 Tablets and Per Unit Cost of 10mg Oral Tablet (US$), February’2022

Figure 12-34: Ritalin - Cost of 100 Tablets and Per Unit Cost of 20mg Oral Tablet (US$), February’2022

Figure 12-35: Methlyphenidate - Cost of Supply of 30, 100 and 500 5mg Oral Tablets (US$), February’2022

Figure 12-36: Methlyphenidate - Cost of Supply of 30, 50, 100 and 500 10mg Oral Tablets (US$), February’2022

Figure 12-37: Methlyphenidate - Cost of Supply of 50, 100 and 500 20mg Oral Tablets (US$), February’2022

Figure 12-38: Methlyphenidate – Recommended Initial and Maximum Dose for Adult Patients (mg)

Figure 12-39: Methlyphenidate – Recommended Initial and Maximum Dose for Pediatric Patients (mg)

Figure 12-40: Renagel - Approval Year by Region

Figure 12-41: US - Renagel FDA Approval and First Generic Approval Year

Figure 12-42: US - Cost of 180 Tablets and Per Unit Cost of Renagel 800mg Oral Tablet (US$), February’2022

Figure 12-43: UK - Cost of 180 Tablets and Per Unit Cost of Renagel 800mg Oral Tablet (GBP/US$), February’2022

Figure 12-44: US - Cost of 100 Tablets and Per Unit Cost of Sevelamer 800mg Oral Tablet (US$), February’2022

Figure 12-45: US - Cost of 180 Tablets and Per Unit Cost of Sevelamer 800mg Oral Tablet (US$), February’2022

Figure 12-46: Renagel – Recommended Initial Dose by Serum Phosphorus Levels (mg/day)

Figure 12-47: Abelcet - Cost of 20ml and Per Unit Cost of 5mg/ml Intravenous Solution (US$), February’2022

Figure 12-48: Somavert - Approval Year by Region

Figure 12-49: US - Per Unit Cost of Somavert Subcutaneous Powder by Strength (US$), February’2022

Figure 12-50: US - Cost of Supply of 30 Somavert Subcutaneous Powders by Strength (US$), February’2022

Figure 12-51: UK - Cost of Supply of 30 Somavert Subcutaneous Powders by Strength (GBP/US$), February’2022

Figure 12-52: Somavert – Recommended Minimum and Maximum Daily Dosage (mg/day)

Figure 12-53: Rebinyn/Refixia- Patent Exclusivity by Region

Figure 12-54: UK - Cost of Supply of Refixia Subcutaneous Powders by Strength (GBP/US$), February’2022

Figure 12-55: Rebinyn – Recommended Dosage by Type of Bleeding (IU/KG)

Figure 12-56: Invega - Approval Year by Region

Figure 12-57: US - Renagel FDA Approval and First Generic Approval Year

Figure 12-58: US - Cost of 30 Tablets and Per Unit Cost of Invega 1.5mg, 3mg, and 6mg Oral Extended Release Tablet (US$), February’2022

Figure 12-59: US - Cost of 30 Tablets and Per Unit Cost of Invega 9mg Oral Extended Release Tablet (US$), February’2022

Figure 12-60: UK - Cost of 28 Tablets and Per Unit Cost of Invega 3mg and 6mg Oral Extended Release Tablet (GBP/US$), February’2022

Figure 12-61: UK - Cost of 28 Tablets and Per Unit Cost of Invega 9mgOral Extended Release Tablet (GBP/US$), February’2022

Figure 12-62: Invega – Recommended Initial Dosage for Schizophrenia by Age (mg/day)

Figure 12-63: Invega – Recommended Initial and Maximum Dosage for Schizophrenia in Adults (mg/day)

Figure 13-1: Global – Ambisome Annual Sales (US$ Million), 2018 - 2021

Figure 13-2: Europe – Ambisome Annual Sales (US$ Million), 2018 - 2021

Figure 13-3: US – Ambisome Annual Sales (US$ Million), 2018 - 2021

Figure 13-4: ROW – Ambisome Annual Sales (US$ Million), 2018 - 2021

Figure 13-5: Ambisome – Annual Sales by Region (US$ Million), 2021

Figure 13-6: Ambisome – Annual Sales by Region (%), 2021

Figure 13-7: Global – Ambisome Quaterly Sales (US$ Million), 2021

Figure 13-8: Global – Ambisome Quaterly Sales (US$ Million), 2020

Figure 13-9: Global – Ambisome Sales Forecast (US$ Million), 2022 - 2028

Figure 13-10: US – Ambisome Sales Forecast (US$ Million), 2022 - 2028

Figure 13-11: Europe – Ambisome Sales Forecast (US$ Million), 2022 - 2028

Figure 13-12: Global – Abraxane Annual Sales (US$ Million), 2019 - 2021

Figure 13-13: US – Abraxane Annual Sales (US$ Million), 2019 - 2021

Figure 13-14: Abraxane - Annual Sales by Region (US$ Million), 2021

Figure 13-15: Abraxane - Annual Sales by Region (%), 2021

Figure 13-16: Global – Abraxane Quaterly Sales (US$ Million), 2021

Figure 13-17: Global – Abraxane Quaterly Sales (US$ Million), 2020

Figure 13-18: US – Abraxane Quaterly Sales (US$ Million), 2021

Figure 13-19: US – Abraxane Quaterly Sales (US$ Million), 2020

Figure 13-20: Global – Abraxane Sales Forecast (US$ Million), 2022 - 2028

Figure 13-21: US – Abraxane Sales Forecast (US$ Million), 2022 - 2028

Figure 13-22: Global – Vyxeos Quaterly Sales (US$ Million), Q1-Q3’2021

Figure 13-23: Global – Vyxeos 9 Months Sales (US$ Million), 2020 and 2021

Figure 13-24: Global – Vyxeos Annual Sales (US$ Million), 2019 and 2020

Figure 13-25: Global – Vyxeos Quaterly Sales (US$ Million), 2020

Figure 13-26: Global – Vyxeos Sales Forecast (US$ Million), 2022 - 2028

Figure 13-27: Global – Onpattro Annual Sales (US$ Million), 2018 - 2021

Figure 13-28: Global – Onpattro Quaterly Sales (US$ Million), 2021

Figure 13-29: Global – Onpattro Quaterly Sales (US$ Million), 2020

Figure 13-30: Global – Onpattro Sales Forecast (US$ Million), 2022 - 2028

Figure 13-31: Global – Neulasta Annual Sales (US$ Million), 2018 - 2021

Figure 13-32: US – Neulasta Annual Sales (US$ Million), 2019 - 2021

Figure 13-33: ROW – Neulasta Annual Sales (US$ Million), 2019 - 2021

Figure 13-34: Neulasta - Annual Sales by Region (US$ Million), 2021

Figure 13-35: Neulasta - Annual Sales by Region (%), 2021

Figure 13-36: Global – Neulasta Quaterly Sales (US$ Million), 2021

Figure 13-37: Global – Neulasta Quaterly Sales (US$ Million), 2020

Figure 13-38: US – Neulasta Quaterly Sales (US$ Million), 2021

Figure 13-39: Global – Neulasta Sales Forecast (US$ Million), 2022 - 2028

Figure 13-40: US – Neulasta Sales Forecast (US$ Million), 2022 - 2028

Figure 13-41: Global – Somavert Annual Sales (US$ Million), 2018 - 2021

Figure 13-42: US – Somavert Annual Sales (US$ Million), 2018 - 2021

Figure 13-43: Europe – Somavert Annual Sales (US$ Million), 2018 - 2021

Figure 13-44: Somavert – Annual Sales by Region (US$ Million), 2021

Figure 13-45: Somavert – Annual Sales by Region (%), 2021

Figure 13-46: Global – Somavert Quaterly Sales (US$ Million), 2021

Figure 13-47: Global – Somavert Quaterly Sales (US$ Million), 2020

Figure 13-48: US – Somavert Quaterly Sales (US$ Million), 2021

Figure 13-49: US – Somavert Quaterly Sales (US$ Million), 2020

Figure 13-50: Global – Somavert Sales Forecast (US$ Million), 2022 - 2028

Figure 13-51: US – Somavert Sales Forecast (US$ Million), 2022 - 2028

Figure 13-52: Europe – Somavert Sales Forecast (US$ Million), 2022 - 2028

Figure 13-53: ROW – Somavert Sales Forecast (US$ Million), 2022 - 2028

Figure 13-54: Global – Zilretta Quaterly Sales (US$ Million), Q1 and Q2’2021

Figure 13-55: Global – Zilretta Half Year Sales (US$ Million), H1’2021 and H1’2020

Figure 13-56: Global – Zilretta Quaterly Sales (US$ Million), 2020

Figure 13-57: Global – Zilretta Sales Forecast (US$ Million), 2022 - 2028

Figure 13-58: Global - Copaxone Sales Value (US$ Billion), 2018 - 2021

Figure 13-59: Global - Copaxone Sales by Region (US$ Million), 2021

Figure 13-60: Global - Copaxone Sales by Region (US$ Million), 2020

Figure 13-61: Global - Copaxone Sales by Region (%), 2021

Figure 13-62: Global - Copaxone Sales by Region (%), 2020

Figure 13-63: Global - Copaxone Sales Forecast (US$ Million), 2022 - 2028

Figure 13-64: US - Copaxone Sales Forecast (US$ Million), 2022 - 2028

Figure 13-65: Global – Mircera Annual Sales (CHF/US$ Million), 2019 - 2021

Figure 13-66: Global – Mircera Half Year Sales (CHF/US$ Million), 2019 - 2021

Figure 13-67: Global - Mircera Sales Forecast (US$ Million), 2022 - 2028

Figure 13-68: Global – Injectafer Annual Sales (CHF/US$ Million), 2019 - 2021

Figure 13-69: Global – Injectafer Half Year Sales (CHF/US$ Million), 2019 - 2021

Figure 13-70: Global – Injectafer Sales Forecast (US$ Million), 2022 - 2028

Figure 13-71: Global – Venofer Annual Sales (CHF/US$ Million), 2019 - 2021

Figure 13-72: Global – Venofer Half Year Sales (CHF/US$ Million), 2019 - 2021

Figure 13-73: Global – Venofer Sales Forecast (US$ Million), 2022 - 2028

Figure 13-74: Global – Onivyde Annual Sales (Euro/US$ Million), 2018 - 2021

Figure 13-75: Global – Onivyde Quaterely Sales (Euro/US$ Million), 2021

Figure 13-76: Global – Onivyde Quaterely Sales (Euro/US$ Million), 2020

Figure 13-77: Global – Onivyde Sales Forecast (US$ Million), 2022 - 2028

Figure 13-78: Global – Cimzia Half Year Sales (Euro/US$ Million), 2020 and 2021

Figure 13-79: Global – Cimzia Annual Sales (Euro/US$ Million), 2019 and 2020

Figure 13-80: Global – Cimzia Sales Forecast (US$ Million), 2022 - 2028

Figure 13-81: Global – Plegridy Annual Sales (US$ Million), 2018 - 2021

Figure 13-82: US – Plegridy Annual Sales (US$ Million), 2020 and 2021

Figure 13-83: Plegridy - Annual Sales by Region (US$ Million), 2021

Figure 13-84: Plegridy - Annual Sales by Region (%), 2021

Figure 13-85: Global – Plegridy Quaterly Sales (US$ Million), 2021

Figure 13-86: US – Plegridy Quaterly Sales (US$ Million), 2021

Figure 13-87: Global – Plegridy Sales Forecast (US$ Million), 2022 - 2028

Figure 13-88: US – Plegridy Sales Forecast (US$ Million), 2022 - 2028

Figure 13-89: Global – Krystexxa Quaterly Sales (US$ Million), Q1-Q3’2021

Figure 13-90: Global – Krystexxa 9 Months Sales (US$ Million), 2020 and 2021

Figure 13-91: Global – Krystexxa Annual Sales (US$ Million), 2019 and 2020

Figure 13-92: Global – Krystexxa Quaterly Sales (US$ Million), 2020

Figure 13-93: Global – Krystexxa Sales Forecast (US$ Million), 2022 - 2028

Figure 14-1: Global Nanoparticle Drug – Number of Clinical Trials by Status, February’2021

Figure 14-2: Global Nanoparticle Drug – Number of Clinical Trials by Status (%), February’2021

Figure 14-3: Global Nanoparticle Drug – Number of Clinical Trials by Phase, February’2021

Figure 14-4: Global Nanoparticle Drug – Number of Clinical Trials by Phase (%), February’2021

Figure 14-5: Global Nanoparticle Drug – Number of Clinical Trials by Region, February’2021

Figure 14-6: Global Nanoparticle Drug – Number of Clinical Trials by Region (%), February’2021

Figure 15-1: Global Nanoparticle Drug – Number of Clinical Trials by Phase, February’2021

Figure 17-1: Nanoparticle Drug Delivery - Driving Factors

Figure 17-2: Magnetic Nanoparticle - Recent Advances in Drug Delivery

Figure 17-3: Nanoparticle Drug Delivery Market Challenges

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected